{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:56:21Z","timestamp":1781157381177,"version":"3.54.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.hoc.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:05:06Z","timestamp":1781136306000},"page":"347-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations"],"prefix":"10.1016","volume":"40","author":[{"given":"Jennifer A.","family":"Belsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Shoag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Harker-Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine M.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2026.02.005_bib1","series-title":"Surveillance, epidemiology, and end results (SEER) program","year":"2019"},{"issue":"7","key":"10.1016\/j.hoc.2026.02.005_bib2","doi-asserted-by":"crossref","first-page":"e27033","DOI":"10.1002\/pbc.27033","article-title":"Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care","volume":"65","author":"Kahn","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2026.02.005_bib3","unstructured":"Institute NC. Survelliance, Epidemiology, and End Results Program. In: Hodgkin Lymphoma SEER 2015-2019, 2019."},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.15640","article-title":"Current considerations in AYA Hodgkin lymphoma","volume":"184","author":"Crombie","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2008.07393.x","article-title":"Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science","volume":"144","author":"Hochberg","year":"2009","journal-title":"Br J Haematol"},{"issue":"17","key":"10.1016\/j.hoc.2026.02.005_bib6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","article-title":"Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries","volume":"126","author":"Kharazmi","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.005_bib7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/PPO.0b013e3181a39585","article-title":"Current insight on trends, causes, and mechanisms of Hodgkin\u2019s lymphoma","volume":"15","author":"Caporaso","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.hoc.2026.02.005_bib8","article-title":"Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma","author":"Flerlage","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2026.02.005_bib9","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/jcp.2007.050146","article-title":"Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma","volume":"60","author":"Kapatai","year":"2007","journal-title":"J Clin Pathol"},{"issue":"21","key":"10.1016\/j.hoc.2026.02.005_bib10","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood.V116.21.766.766","article-title":"AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children\u2019s Oncology Group","volume":"116","author":"Friedman","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib11","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.005_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijrobp.2021.07.1716","article-title":"Radiation Therapy Across Pediatric Hodgkin Lymphoma Research Group Protocols: A Report From the Staging, Evaluation, and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL) Group","volume":"112","author":"Hall","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ijrobp.2018.03.002","article-title":"The Children\u2019s Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer","volume":"101","author":"Breneman","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"32","key":"10.1016\/j.hoc.2026.02.005_bib14","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.02.005_bib15","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children\u2019s Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.hoc.2026.02.005_bib16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16014","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children\u2019s Oncology Group","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.02.005_bib18","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1200\/JCO.2022.40.16_suppl.7504","article-title":"Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children\u2019s Oncology Group phase 3 study AHOD1331 (NCT 02166463)","volume":"40","author":"Castellino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.02.005_bib19","doi-asserted-by":"crossref","first-page":"TPS8067","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8067","article-title":"An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826","volume":"38","author":"Castellino","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26278","article-title":"Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children\u2019s Oncology Group","volume":"64","author":"Schwartz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"10.1016\/j.hoc.2026.02.005_bib21","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1182\/blood.V118.21.3649.3649","article-title":"The Childhood Hodgkin International Prognostic Score (CHIPS) for Predicting Event Free Survival in Pediatric and Adolescent Hodgkin Lymphoma","volume":"118","author":"Schwartz","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib22","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","article-title":"Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials","volume":"9","author":"Kahn","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2026.02.005_bib23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","article-title":"State of the art in the treatment of Hodgkin lymphoma","volume":"9","author":"Borchmann","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.hoc.2026.02.005_bib24","article-title":"Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease","author":"Sobesky","year":"2021","journal-title":"medRxiv"},{"issue":"22","key":"10.1016\/j.hoc.2026.02.005_bib25","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2026.02.005_bib26","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2026.02.005_bib27","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: report from the Late Effects Study Group","volume":"21","author":"Bhatia","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.02.005_bib28","first-page":"40","article-title":"Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children\u2019s Oncology Group phase 3 study AHOD1331","author":"Sharon","year":"2022","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.02.005_bib29","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"0","key":"10.1016\/j.hoc.2026.02.005_bib30","article-title":"Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial","volume":"0","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2026.02.005_bib31","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2026.02.005_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102887","article-title":"Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma","volume":"12","author":"Voorhees","year":"2020","journal-title":"Cancers"},{"issue":"9323","key":"10.1016\/j.hoc.2026.02.005_bib34","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8852","key":"10.1016\/j.hoc.2026.02.005_bib35","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/pbc.25205","article-title":"Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory\/relapsed Hodgkin lymphoma, AHOD00P1: a children\u2019s oncology group report","volume":"62","author":"Trippett","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.005_bib37","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2008.20.3778","article-title":"Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin\u2019s disease: a children\u2019s oncology group report","volume":"27","author":"Cole","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.005_bib38","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.02.005_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11899-018-0484-4","article-title":"Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma","volume":"13","author":"Hu","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2026.02.005_bib41","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.005_bib42","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib43","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/pbc.24851","article-title":"Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma","volume":"61","author":"Harker-Murray","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2026.02.005_bib44","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/cncr.30089","article-title":"Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma","volume":"122","author":"Kahn","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib45","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/jayao.2021.0131","article-title":"Racial Disparities in Children, Adolescents, and Young Adults with Hodgkin Lymphoma Enrolled in the New York State Medicaid Program","volume":"11","author":"Kahn","year":"2022","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"24","key":"10.1016\/j.hoc.2026.02.005_bib46","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1002\/cncr.33868","article-title":"Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population-based study","volume":"127","author":"Kahn","year":"2021","journal-title":"Cancer"},{"issue":"32","key":"10.1016\/j.hoc.2026.02.005_bib47","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.19.00812","article-title":"Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children\u2019s Oncology Group Study","volume":"37","author":"Kahn","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.02.005_bib48","unstructured":"Cancer Facts & Figures 2021. In: American Cancer Society."},{"issue":"22","key":"10.1016\/j.hoc.2026.02.005_bib49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/bloodadvances.2017008748","article-title":"Adolescent and young adult lymphoma: collaborative efforts toward optimizing care and improving outcomes","volume":"1","author":"Kahn","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.hoc.2026.02.005_bib50","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1200\/JOP.19.00450","article-title":"Evaluation of Adolescents\u2019 and Young Adults\u2019 Attitudes Toward Participation in Cancer Clinical Trials","volume":"16","author":"Lewin","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"24","key":"10.1016\/j.hoc.2026.02.005_bib51","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1002\/cncr.33855","article-title":"Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years","volume":"127","author":"Unger","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.30979","article-title":"Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis","volume":"124","author":"Henderson","year":"2018","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.005_bib53","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1055-9965.EPI-21-0103","article-title":"Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors","volume":"30","author":"Berkman","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.hoc.2026.02.005_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16197","article-title":"Closing the survivorship gap in children and adolescents with Hodgkin lymphoma","volume":"187","author":"Castellino","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2026.02.005_bib55","first-page":"551","article-title":"Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors","volume":"29","author":"Keegan","year":"2018","journal-title":"Cancer Causes Control"},{"issue":"15","key":"10.1016\/j.hoc.2026.02.005_bib56","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMsa060185","article-title":"Chronic health conditions in adult survivors of childhood cancer","volume":"355","author":"Oeffinger","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2026.02.005_bib57","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.005_bib58","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/0284186X.2016.1267404","article-title":"Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry","volume":"56","author":"Husson","year":"2017","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.02.005_bib59","doi-asserted-by":"crossref","first-page":"e27660","DOI":"10.1002\/pbc.27660","article-title":"Understanding, measuring, and addressing the financial impact of cancer on adolescents and young adults","volume":"66","author":"Salsman","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib60","article-title":"Young Adult Cancer Survivorship: Recommendations for Patient Follow-up, Exercise Therapy, and Research","volume":"5","author":"Adams","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.hoc.2026.02.005_bib61","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1200\/EDBK_320499","article-title":"Disparities in Pediatric Oncology: The 21st Century Opportunity to Improve Outcomes for Children and Adolescents With Cancer","volume":"41","author":"Aristizabal","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.hoc.2026.02.005_bib62","first-page":"277s","article-title":"Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials","volume":"12","author":"Christian","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.hoc.2026.02.005_bib63","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cncr.31114","article-title":"Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma","volume":"124","author":"Myers","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2026.02.005_bib64","doi-asserted-by":"crossref","first-page":"e29195","DOI":"10.1002\/pbc.29195","article-title":"PediCARE: Development of a poverty-targeted intervention for pediatric cancer","volume":"68","author":"Umaretiya","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"10.1016\/j.hoc.2026.02.005_bib65","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin\u2019s lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2026.02.005_bib66","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.02.005_bib67","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2001.19.9.2390","volume":"19","author":"Kobrinsky","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00043426-200101000-00008","article-title":"Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children\u2019s cancer group report","volume":"23","author":"Cairo","year":"2001","journal-title":"Journal of pediatric hematology\/oncology"},{"issue":"25","key":"10.1016\/j.hoc.2026.02.005_bib69","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1200\/JCO.2005.07.930","article-title":"Salvage therapy of progressive and recurrent Hodgkin\u2019s disease: results from a multicenter study of the pediatric DAL\/GPOH-HD study group","volume":"23","author":"Schellong","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.02.005_bib70","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/pbc.20563","article-title":"APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial","volume":"46","author":"Wimmer","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.hoc.2026.02.005_bib71","article-title":"A pilot study of re-induction chemotherapy with Ifosfamide, and Vinorelbine (IV) in children with refractory\/relapsed Hodgkin disease, AHOD00P1 [abstract]","volume":"73","author":"Trippett","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.hoc.2026.02.005_bib72","article-title":"A pilot study of re-induction chemotherapy with Ifosfamide, and Vinorelbine (IV) in children with refractory\/relapsed Hodgkin disease, AHOD00P1","author":"Trippett","year":"2008","journal-title":"Children\u2019s oncology group hodgkin lymphoma committee progress report"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.02.005_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.9537","article-title":"A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory\/recurrent Hodgkin disease (HD): A Children\u2019s Oncology Group (COG) study","volume":"28","author":"Horton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.02.005_bib74","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/annonc\/mdq348","article-title":"Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma","volume":"22","author":"Sandlund","year":"2011","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"17","key":"10.1016\/j.hoc.2026.02.005_bib75","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2026.02.005_bib76","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/bloodadvances.2019000984","article-title":"Five-year results of the BEGEV salvage regimen in relapsed\/refractory classical Hodgkin lymphoma","volume":"4","author":"Santoro","year":"2020","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:26Z","timestamp":1781153786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0889858826000067"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.02.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}